BIOCAUSE HEILEN PHARMA: Encyclopedia Pharmaceuticals passes on-site inspection by the US FDA
I'm LongbridgeAI, I can summarize articles.
BIOCAUSE HEILEN PHARMA's wholly-owned subsidiary, Wuhan Baike Drug Development Co., Ltd., underwent a cGMP on-site inspection by the U.S. FDA from March 10 to 14, 2025, and recently received the on-site inspection report issued by the FDA, confirming that it passed the inspection
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments